Tags

Type your tag names separated by a space and hit enter

Vaccination against IL-33 Inhibits Airway Hyperresponsiveness and Inflammation in a House Dust Mite Model of Asthma.
PLoS One 2015; 10(7):e0133774Plos

Abstract

In several clinical and experimental studies IL-33 and its receptor have been found to play important roles in the development of asthma and allergic airway inflammation. We evaluated the effects of vaccination against IL-33 in a mouse model of airway inflammation induced by house dust mite (HDM) allergen. Balb/c mice received the IL-33 vaccine subcutaneously, followed by intranasal administration of HDM for up to six weeks. Vaccination against IL-33 induced high titers of specific anti-IL-33 IgG antibodies that inhibited HDM-induced airway hyperresponsiveness (AHR) in the conducting airways and tissue damping. The vaccination also attenuated the HDM-induced elevation in the numbers of eosinophils in bronchoalveolar lavage fluid (BALF) and suppressed the accumulation of inflammatory cells in the airways. Furthermore, the levels of IL-17A, IL-25, IL-33 and TSLP in lung tissue homogenates were reduced by vaccination against IL-33. These observations demonstrate that vaccination against IL-33 inhibits HDM-induced development of AHR, airway inflammation and production of inflammatory cytokines. The results also indicate an important role of IL-33 in the regulation of AHR of the distal lung compartments. Thus, administration of such a vaccine is potentially an effective therapeutic tool for treating allergic asthma.

Authors+Show Affiliations

Department of Medicine, Clinical Immunology and Allergy Unit, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden; Department of Pharmacy, The Second Affiliated Hospital, School of Medicine, Xi'an Jiaotong University, Xi'an, China.Department of Cell and Molecular Biology, Uppsala University, Uppsala, Sweden.Department of Medicine, Clinical Immunology and Allergy Unit, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Center for Allergy Research, Karolinska Institutet, Stockholm, Sweden.Department of Cell and Molecular Biology, Uppsala University, Uppsala, Sweden.Department of Medicine, Clinical Immunology and Allergy Unit, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden; Center for Allergy Research, Karolinska Institutet, Stockholm, Sweden.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

26214807

Citation

Lei, Ying, et al. "Vaccination Against IL-33 Inhibits Airway Hyperresponsiveness and Inflammation in a House Dust Mite Model of Asthma." PloS One, vol. 10, no. 7, 2015, pp. e0133774.
Lei Y, Boinapally V, Zoltowska A, et al. Vaccination against IL-33 Inhibits Airway Hyperresponsiveness and Inflammation in a House Dust Mite Model of Asthma. PLoS ONE. 2015;10(7):e0133774.
Lei, Y., Boinapally, V., Zoltowska, A., Adner, M., Hellman, L., & Nilsson, G. (2015). Vaccination against IL-33 Inhibits Airway Hyperresponsiveness and Inflammation in a House Dust Mite Model of Asthma. PloS One, 10(7), pp. e0133774. doi:10.1371/journal.pone.0133774.
Lei Y, et al. Vaccination Against IL-33 Inhibits Airway Hyperresponsiveness and Inflammation in a House Dust Mite Model of Asthma. PLoS ONE. 2015;10(7):e0133774. PubMed PMID: 26214807.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Vaccination against IL-33 Inhibits Airway Hyperresponsiveness and Inflammation in a House Dust Mite Model of Asthma. AU - Lei,Ying, AU - Boinapally,Vamsi, AU - Zoltowska,Anna, AU - Adner,Mikael, AU - Hellman,Lars, AU - Nilsson,Gunnar, Y1 - 2015/07/27/ PY - 2015/03/13/received PY - 2015/07/01/accepted PY - 2015/7/28/entrez PY - 2015/7/28/pubmed PY - 2016/5/6/medline SP - e0133774 EP - e0133774 JF - PloS one JO - PLoS ONE VL - 10 IS - 7 N2 - In several clinical and experimental studies IL-33 and its receptor have been found to play important roles in the development of asthma and allergic airway inflammation. We evaluated the effects of vaccination against IL-33 in a mouse model of airway inflammation induced by house dust mite (HDM) allergen. Balb/c mice received the IL-33 vaccine subcutaneously, followed by intranasal administration of HDM for up to six weeks. Vaccination against IL-33 induced high titers of specific anti-IL-33 IgG antibodies that inhibited HDM-induced airway hyperresponsiveness (AHR) in the conducting airways and tissue damping. The vaccination also attenuated the HDM-induced elevation in the numbers of eosinophils in bronchoalveolar lavage fluid (BALF) and suppressed the accumulation of inflammatory cells in the airways. Furthermore, the levels of IL-17A, IL-25, IL-33 and TSLP in lung tissue homogenates were reduced by vaccination against IL-33. These observations demonstrate that vaccination against IL-33 inhibits HDM-induced development of AHR, airway inflammation and production of inflammatory cytokines. The results also indicate an important role of IL-33 in the regulation of AHR of the distal lung compartments. Thus, administration of such a vaccine is potentially an effective therapeutic tool for treating allergic asthma. SN - 1932-6203 UR - https://www.unboundmedicine.com/medline/citation/26214807/Vaccination_against_IL_33_Inhibits_Airway_Hyperresponsiveness_and_Inflammation_in_a_House_Dust_Mite_Model_of_Asthma_ L2 - http://dx.plos.org/10.1371/journal.pone.0133774 DB - PRIME DP - Unbound Medicine ER -